JP2000506847A - 4―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法 - Google Patents
4―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法Info
- Publication number
- JP2000506847A JP2000506847A JP9531444A JP53144497A JP2000506847A JP 2000506847 A JP2000506847 A JP 2000506847A JP 9531444 A JP9531444 A JP 9531444A JP 53144497 A JP53144497 A JP 53144497A JP 2000506847 A JP2000506847 A JP 2000506847A
- Authority
- JP
- Japan
- Prior art keywords
- group
- amino
- piperidinyl
- alkyl
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1996108631 DE19608631A1 (de) | 1996-03-06 | 1996-03-06 | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arnzeimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE19608631.0 | 1996-03-06 | ||
DE19629652A DE19629652A1 (de) | 1996-03-06 | 1996-07-23 | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE19629652.8 | 1996-07-23 | ||
PCT/EP1997/001057 WO1997032881A1 (de) | 1996-03-06 | 1997-03-03 | 4-amino-pyrimidin-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000506847A true JP2000506847A (ja) | 2000-06-06 |
Family
ID=26023531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9531444A Pending JP2000506847A (ja) | 1996-03-06 | 1997-03-03 | 4―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0885226A1 (cs) |
JP (1) | JP2000506847A (cs) |
KR (1) | KR19990087550A (cs) |
CN (1) | CN1212695A (cs) |
AU (1) | AU710274B2 (cs) |
BG (1) | BG102708A (cs) |
BR (1) | BR9708312A (cs) |
CA (1) | CA2243994A1 (cs) |
CZ (1) | CZ281798A3 (cs) |
DE (1) | DE19629652A1 (cs) |
EE (1) | EE9800277A (cs) |
HU (1) | HUP9901820A3 (cs) |
IL (1) | IL125404A0 (cs) |
NO (1) | NO984084L (cs) |
NZ (1) | NZ331546A (cs) |
PL (1) | PL328771A1 (cs) |
SK (1) | SK120598A3 (cs) |
TR (1) | TR199801749T2 (cs) |
WO (1) | WO1997032881A1 (cs) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008530212A (ja) * | 2005-02-16 | 2008-08-07 | シェーリング コーポレイション | Cxcr3アンタゴニスト活性を有するピペラジン−ピペリジン |
JP2012510481A (ja) * | 2008-12-01 | 2012-05-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌に対するオータキシン阻害剤としての2,5−ジアミノ−置換ピリド[4,3−d]ピリミジン |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
ES2306306T3 (es) | 1999-11-05 | 2008-11-01 | Astrazeneca Ab | Nuevos derivados de quinazolina. |
BRPI0411608A (pt) | 2003-06-24 | 2006-08-08 | Neurosearch As | derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo |
CA2742986C (en) | 2008-11-07 | 2015-03-31 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
US20120316187A1 (en) | 2009-11-13 | 2012-12-13 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
CN104024432B (zh) | 2011-08-31 | 2017-02-22 | 基因泰克公司 | 诊断性标志物 |
JP2014531213A (ja) | 2011-09-30 | 2014-11-27 | ジェネンテック, インコーポレイテッド | 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるegfrキナーゼ阻害薬に対する応答 |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | CANCER THERAPY |
US20160051556A1 (en) | 2013-03-21 | 2016-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression |
US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
SG11201704852SA (en) | 2014-12-24 | 2017-07-28 | Genentech Inc | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
JOP20190154B1 (ar) | 2016-12-22 | 2022-09-15 | Amgen Inc | بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
EP4141005B1 (en) | 2017-09-08 | 2024-04-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
WO2019213526A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
MA52765A (fr) | 2018-06-01 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MA52780A (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
MA51848A (fr) | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
CA3117221A1 (en) | 2018-11-16 | 2020-05-22 | Amgen Inc. | Improved synthesis of key intermediate of kras g12c inhibitor compound |
AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CA3123044A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
CN113226473A (zh) | 2018-12-20 | 2021-08-06 | 美国安进公司 | Kif18a抑制剂 |
MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
KR20210146287A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CN114144414A (zh) | 2019-05-21 | 2022-03-04 | 美国安进公司 | 固态形式 |
AU2020326627A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
JP2022542392A (ja) | 2019-08-02 | 2022-10-03 | アムジエン・インコーポレーテツド | Kif18a阻害剤としてのピリジン誘導体 |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
BR112022008565A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras |
TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
KR20220100903A (ko) | 2019-11-08 | 2022-07-18 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
MX2022005708A (es) | 2019-11-14 | 2022-06-08 | Amgen Inc | Sintesis mejorada del compuesto inhibidor de g12c de kras. |
AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
AU2021206217A1 (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines, Inc. | SHP2 inhibitor dosing and methods of treating cancer |
JP2023530351A (ja) | 2020-06-18 | 2023-07-14 | レヴォリューション・メディスンズ,インコーポレイテッド | Ras阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法 |
IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
AU2021345111A1 (en) | 2020-09-15 | 2023-04-06 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
MX2023013084A (es) | 2021-05-05 | 2023-11-17 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer. |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
DE4431867A1 (de) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
1996
- 1996-07-23 DE DE19629652A patent/DE19629652A1/de not_active Ceased
-
1997
- 1997-03-03 BR BR9708312A patent/BR9708312A/pt not_active IP Right Cessation
- 1997-03-03 TR TR1998/01749T patent/TR199801749T2/xx unknown
- 1997-03-03 JP JP9531444A patent/JP2000506847A/ja active Pending
- 1997-03-03 CA CA002243994A patent/CA2243994A1/en not_active Abandoned
- 1997-03-03 KR KR1019980706987A patent/KR19990087550A/ko not_active Application Discontinuation
- 1997-03-03 EP EP97907066A patent/EP0885226A1/de not_active Ceased
- 1997-03-03 SK SK1205-98A patent/SK120598A3/sk unknown
- 1997-03-03 CZ CZ982817A patent/CZ281798A3/cs unknown
- 1997-03-03 PL PL97328771A patent/PL328771A1/xx unknown
- 1997-03-03 EE EE9800277A patent/EE9800277A/xx unknown
- 1997-03-03 AU AU19251/97A patent/AU710274B2/en not_active Ceased
- 1997-03-03 IL IL12540497A patent/IL125404A0/xx unknown
- 1997-03-03 WO PCT/EP1997/001057 patent/WO1997032881A1/de not_active Application Discontinuation
- 1997-03-03 NZ NZ331546A patent/NZ331546A/xx unknown
- 1997-03-03 CN CN97192787A patent/CN1212695A/zh active Pending
- 1997-03-03 HU HU9901820A patent/HUP9901820A3/hu unknown
-
1998
- 1998-08-20 BG BG102708A patent/BG102708A/xx unknown
- 1998-09-04 NO NO984084A patent/NO984084L/no unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008530212A (ja) * | 2005-02-16 | 2008-08-07 | シェーリング コーポレイション | Cxcr3アンタゴニスト活性を有するピペラジン−ピペリジン |
JP2012510481A (ja) * | 2008-12-01 | 2012-05-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌に対するオータキシン阻害剤としての2,5−ジアミノ−置換ピリド[4,3−d]ピリミジン |
Also Published As
Publication number | Publication date |
---|---|
CA2243994A1 (en) | 1997-09-12 |
BG102708A (en) | 1999-09-30 |
IL125404A0 (en) | 1999-03-12 |
EE9800277A (et) | 1999-02-15 |
BR9708312A (pt) | 1999-08-03 |
NO984084D0 (no) | 1998-09-04 |
HUP9901820A3 (en) | 2001-10-29 |
WO1997032881A1 (de) | 1997-09-12 |
DE19629652A1 (de) | 1998-01-29 |
TR199801749T2 (xx) | 1998-12-21 |
NO984084L (no) | 1998-09-04 |
SK120598A3 (en) | 1999-06-11 |
AU710274B2 (en) | 1999-09-16 |
EP0885226A1 (de) | 1998-12-23 |
CZ281798A3 (cs) | 1999-02-17 |
AU1925197A (en) | 1997-09-22 |
CN1212695A (zh) | 1999-03-31 |
NZ331546A (en) | 2000-03-27 |
KR19990087550A (ko) | 1999-12-27 |
PL328771A1 (en) | 1999-02-15 |
HUP9901820A2 (hu) | 1999-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000506847A (ja) | 4―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法 | |
EP2661435B1 (en) | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
AU730376B2 (en) | Pyrimido{5,4-d}pyrimidines, medicaments containing these compounds, their use and process for their production | |
TWI557123B (zh) | 結晶型(8S,9R)-5-氟-8-(4-氟苯基)-9-(1-甲基-1H-1,2,4-三唑-5-基)-8,9-二氫-2H-吡啶并[4,3,2-de]呔-3(7H)-酮甲苯磺酸鹽 | |
CN1066149C (zh) | 用作磷酸二酯酶iv抑制剂的二氮杂䓬并吲哚 | |
KR20190016976A (ko) | Pi3k 베타 저해제로서의 아자벤즈이미다졸 유도체 | |
EA005098B1 (ru) | Бициклические гетероциклы и фармацевтические композиции, содержащие эти соединения | |
EA005679B1 (ru) | Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения | |
DE10042059A1 (de) | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
JP2000506153A (ja) | ピリミド[5,4―d]ピリミジン、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 | |
EP0698025B1 (en) | Ampa antagonists and a method of treatment therewith | |
BG63874B1 (bg) | Производни на индол-2,3-дион-3-оксим | |
JPH03200786A (ja) | ラクタム誘導体 | |
WO2019120194A1 (zh) | 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途 | |
TW202313606A (zh) | 取代的苯基-1h-吡咯并[2,3-c]吡啶衍生物 | |
WO2019134573A1 (zh) | 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型 | |
JP2004507537A (ja) | キナゾリン化合物、この化合物を含有する医薬組成物、その使用及びその調製方法 | |
CN114504574B (zh) | 一种2-((2-甲氧基苯基)磺酰基)异吲哚啉类化合物药物制剂及其制备方法 | |
KR20190016954A (ko) | Pi3k 베타 저해제로서의 이환식 피리딘, 피라진, 및 피리미딘 유도체 | |
WO2010122340A2 (en) | Process 738 | |
CN114634453B (zh) | 喹唑啉衍生物制备方法及其应用 | |
DE19608631A1 (de) | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arnzeimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
MXPA98006850A (en) | Derivatives 4-amino-pyrimidine, medications containing these compounds, their use and process for suproducc | |
WO2022112951A1 (en) | Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate | |
CN115403624A (zh) | 一种二芳基硫代乙内酰脲化合物及其制备方法与应用 |